3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Motor Activity
35
Breast Neoplasms
20
Neoplasms
19
Fatigue
9
Prostatic Neoplasms
4
Lung Neoplasms
4
Hematologic Neoplasms
4
Colorectal Neoplasms
4
Obesity
3
Weight Loss
2
Smoking
2
Sedentary Behavior
2
Postoperative Complications
2
Ovarian Neoplasms
2
Mixed Cancer
2
Lymphedema
2
Frailty
2
Colonic Neoplasms
2
Cardiotoxicity
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urologic Neoplasms
1
Urinary Incontinence
1
Stomach Neoplasms
1
Sarcoma
1
Risk Reduction Behavior
1
Rehabilitation After Lung Cancer Surgery
1
Interventions
Cyclophosphamide
17
fludarabine
13
Dexamethasone
12
Cisplatin
12
Rituximab
10
Gemcitabine
9
Paclitaxel
8
Bendamustine Hydrochloride
8
Lenalidomide
7
Decitabine
7
Cytarabine
7
Carboplatin
7
fludarabine phosphate
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Etoposide
6
Bortezomib
6
Radiotherapy
5
Injections
5
Azacitidine
5
camrelizumab
4
apatinib
4
Valproic Acid
4
Thalidomide
4
Procarbazine
4
Oxaliplatin
4
Drug Therapy
4
Bevacizumab
4
Antilymphocyte Serum
4
venetoclax
3
pomalidomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Recurrence
×
Exercise
×
Clear all
NCT02035631
2014-01-14
PREDICOP
Institut Català d'Oncologia
Phase 3
Unknown
2,000 enrolled